ClinicalTrials.gg

Program

TQC2731

A development code. Also written as “TQC2731 injection”, “210mg of TQC2731 injection” and “420mg of TQC2731 injection”.

In Sino Biopharmaceutical's pipeline, TSLP单抗. Its studies are mostly in Nasal Polyps · Asthma · Pulmonary Disease, Chronic Obstructive, led by Sino Biopharmaceutical.

Furthest: phase 3, since Feb 12, 20257 company-led studies, 3 open or runningNext primary completion: Dec 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sino Biopharmaceutical73 open or runningphase 3since Feb 12, 2025Jun 2, 2021Dec 2026phase 2 · NCT06707883
  • Named in Sino Biopharmaceutical’s own pipeline as TQC2731, phase 3, as of Nov 16, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 2, 2021First study: phase 1 study in Asthma Severe Persistent ControlledFirst studyNCT04923607 · 96 enrolled · China
  2. Jun 9, 2022Phase 2 study in AsthmaNCT05472324 · 205 enrolled · China
  3. Sep 1, 2023Phase 2 study in Nasal PolypsNCT06036927 · 80 enrolled · China
  4. May 30, 2024Phase 2 study in Chronic Rhinosinusitis With Nasal PolypsNCT06451640 · 59 enrolled · China
  5. Nov 25, 2024Phase 2 study in Pulmonary Disease, Chronic ObstructiveNCT06707883 · 258 enrolled · China
  6. Feb 12, 2025Phase 3 study in AsthmaNCT06829784 · 660 planned · China
  7. Jul 23, 2025Phase 3 study in Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)NCT07107256 · 246 enrolled · China

Ahead

  1. Dec 2026Primary completion: phase 2 study in Pulmonary Disease, Chronic ObstructiveNCT06707883
  2. Mar 2027Primary completion: phase 3 study in Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)NCT07107256
  3. Dec 2027Primary completion: phase 3 study in AsthmaNCT06829784

TargetBeta

“TSLP单抗”the company's pipeline, read by Claude · source

Other programs on TSLP

ProgramCompanyFurthest phaseStudies
tezepelumabruleAstraZenecaphase 434
tilrekimigPfizerphase 311
lunsekimigSanofiphase 310
felcorekibartGlaxoSmithKlinephase 39
SHR-1905Jiangsu HengRui Medicinephase 37
WIN378rulewindward-biophase 22
CDX-622ruleCelldex Therapeuticsphase 12
HXN-1013ruleHelixon Biotechnology (Suzhou)phase 11
HY6725ruleNewsoara Biopharmaphase 11

Studies

All 7 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07107256Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) · China3Active, not recruitingMar 2027246
NCT06829784Asthma · China3RecruitingDec 2027660
NCT06707883Pulmonary Disease, Chronic Obstructive · China2Active, not recruitingDec 2026258
NCT06451640Chronic Rhinosinusitis With Nasal Polyps · China2CompletedOct 17, 202559
NCT06036927Nasal Polyps · China2CompletedFeb 5, 202580
NCT05472324Asthma · China2CompletedMar 5, 2025205
NCT04923607Asthma Severe Persistent Controlled · China1UNKNOWNAug 25, 202396

How it is read

Names in the registry

  • “TQC2731 injection”, 5 entries
  • “210mg of TQC2731 injection”, 1 entry
  • “420mg of TQC2731 injection”, 1 entry
  • “TQC2731”, 1 entry

Codes read as this program: TQC2731.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.